|
|
|
Welcome to the Quality Counts. For those health conscious consumers and medical professionals that are looking to purchase nutritional supplements, vitamins, herbs, learning about medications, losing weight, health food, low carbs, high protein nutrition, and exercise, you have come to the right place. Quality Counts serves both the medical practitioner and consumer interested in nutritional therapy and alternative medicine.
Home
> Anti-aging Research > Metformin
Glucophage (metformin)
Where to purchase Metformin (don't take unless
under a physician's supervision):
Related Topics:
News & Research:
- Cross-link Breakers and Inhibitors - International Anti-Aging Systems -
"metformin has a dual effect. It lowers blood glucose, (a well-known and established
activity) plus, as new research is revealing, it is an effective inhibitor of cross-linking" - See metformin at IAS.
-
Metformin: The Most Effective Life Extension Drug is Also a Safe, Effective
Weight Loss Drug - IAS Bulletin -
"Metformin is also one of the most
promising anti-aging, life extending drugs available"
-
Glucophage (metformin) - rxlist.com - "With metformin therapy, insulin
secretion remains unchanged while fasting insulin levels and day-long plasma
insulin response may actually decrease"
-
Metabolic syndrome
- CNN - "Doctors believe that the
underlying cause of this cluster of risk factors is resistance to insulin
... Doctors use thiazolidinediones and metformin (Glucophage, Glucophage XR)
to decrease insulin resistance in people with diabetes. These medications
may help improve insulin metabolism in people with metabolic syndrome"
-
Metformin (Glucophage) and bipolar - psycheducation.org -
"In some cases this medication
can decrease abdominal obesity ... Between 10 and 30% of people taking
metformin have a decrease in their B12 levels ... this can show up is
"anemia""
-
Obesity and Fatty Liver disease - MedicineNet.com -
"Doctors also are using medications
to treat non alcoholic fatty liver disease. For example, insulin-sensitizing
agents, such as the thiazolidinediones, pioglitazone (Actos) and
rosiglitazone (Avandia), and metformin (Glucophage) not only help to control
blood glucose in patients with diabetes, but they also improve enzyme levels
in patients with non alcoholic fatty liver disease"
-
Metformin May Have Novel Role as Breast Cancer Drug - oncologystat.com -
"In one recent hypothesis-generating metformin
study, Dr. Josie M.M. Evans and coworkers at the University of Dundee
(Scotland) evaluated roughly 11,876 patients with newly diagnosed type 2
diabetes, of whom 923 were subsequently diagnosed with cancer. The adjusted
relative risk of malignancy in long-term metformin users was reduced by 44%,
compared with nonusers ... In another population-based cohort study ... In
another population-based cohort study, investigators at the Institute of
Health Economics, Edmonton, Alta., identified 10,309 Saskatchewanians with
type 2 diabetes. During an average of 5.4 years of follow-up after their
diagnosis, 407 cancer-related deaths occurred. Cancer mortality was 3.5% in
metformin users, 5.8% in insulin users, and 4.9% in individuals on
sulfonylurea monotherapy. After adjustment in a multivariate Cox regression
analysis, cancer-related mortality was 30% greater in sulfonylurea users
than in metformin users. In insulin users, it was 90% higher than in
metformin users" - See
Metformin
at OffshoreRx.com.
-
Diabetes drug shows promise in reducing risk of cancer, study suggests -
Science Daily, 11/23/11 - "People with Type-2
diabetes are known to be at high risk for several diabetes-associated
cancers, such as breast, liver and pancreatic cancers ... While metformin
has been shown in population studies to reduce the risk of these cancers,
there was no evidence of how it worked ... estrogen and the chemicals caused
the mammospheres to increase in numbers and size. However, with metformin
added, the numbers and size of the mammospheres were dramatically reduced.
While each of the chemicals enhanced growth by different means, metformin
seemed to be able to inhibit their stimulated growth in all cases"
-
Diabetes drug may prevent or delay development of polycystic ovary syndrome,
the most common cause of infertility in women - Science Daily, 6/29/11
-
Some
diabetes drugs are better than others, according to new study - Science
Daily, 4/6/11 - "compared to metformin treatment,
monotherapy with most ISs, including glimepiride, glibenclamide, glipizide
and tolbutamide, was associated with a greater risk of death from any cause,
and a greater risk of heart attacks, stroke or death from cardiovascular
diseases. This was the case both for patients who had already suffered a
heart attack and for patients who had not. Two other ISs, gliclazide and
repaglinide, showed no significant difference to metformin in their
effectiveness in patients with and without a history of heart attacks
...Patients taking metformin had the best outcomes, supporting prior
evidence of metformin benefit and making it the first-line drug recommended
for almost all patients with type 2 diabetes. Compared against this
beneficial drug, most of the ISs were associated with worse outcomes, but
they would almost certainly be similar to, or better, had the comparison
been made against placebo treatment, with the added benefit on kidney, eye,
and nerve disease of the glucose control they yield" - Note:
Why would they have a study like that and not include the #2 diabetes drug a
thiazolidinedione, Actos (pioglitazone). Makes you question their
motives. See
http://www.pharmacytimes.com/media/pdf/PHTM_36.pdf.
-
Diabetes
treatment may also provide protection against endometrial cancer - Science
Daily, 4/5/11 - "Recent research has found that metformin has anti-cancer
properties, e.g., in breast cancer ... samples from PCOS women who had completed
the 6 month course of metformin the rate of spread of endometrial cancer cells
was around 25% lower than in the serum samples from PCOS women who had not
started that treatment"
-
Newer doesn't mean better when it comes to type 2 diabetes drugs -
Science Daily, 3/14/11 - "metformin, an oral drug
that was first approved by the U.S. Food and Drug Administration in 1995,
not only controlled blood sugar, but was also less likely to cause weight
gain or raise cholesterol levels ... even though there are all these newer
drugs, metformin works just as well and has fewer side effects ... while two
drugs worked better than one in those patients whose blood sugar remained
poorly controlled on a single medication, there were also side effects
associated with adding a second medication"
-
Diabetes
drug could work against Alzheimer's, animal study suggests - Science Daily,
11/24/10 - "the diabetes drug metformin counteracts alterations of the cell
structure protein Tau in mice nerve cells. These alterations are a main cause of
the Alzheimer's disease ... If we can confirm that metformin shows also an
effect in humans, it is certainly a good candidate for an effective therapy on
Alzheimer's diseases"
-
Metformin Might Prevent
Colorectal, Lung Cancers - Medscape, 9/3/10 - "The chance observation
that diabetes patients taking metformin have a 40% reduced risk for cancer
triggered intense research interest in this old off-patent drug ... After
about 10% of the mouse lifespan — about 12 weeks — with the highest dose in
the drinking water, we found a 33% reduction in tumor multiplicity and a 34%
reduction in tumor size in the mice. In mice that did not get metformin,
100% got tobacco carcinogen-induced lung tumors ... metformin might prevent
tumors by reducing levels of insulin and IGF-1" - See my
Insulin and Aging
page. There are a lot of studies pointing toward insulin being a major
cause of aging and caner.
-
Well-defined quantity of antioxidants in diet can improve insulin resistance,
study finds - Science Daily, 6/21/10 - "For groups C and D, the researchers
prescribed a diet enriched in antioxidant, with a calculated intake, 800 to
1,000 milligrams a day, coming from fruits and vegetables, but group D also took metformin ... Despite similar weight loss in all the groups, only the two groups
receiving the antioxidant diet (groups C and D) had a significant decrease in
insulin resistance ... Group D had the best improvement in insulin resistance on
some measures of insulin response to an oral glucose tolerance test ... We think
that a total antioxidant level of 800 to 1,000 milligrams a day is safe and
probably not close to the maximum tolerable level"
-
Metformin-Induced Vitamin
B12 Deficiency Presents as Peripheral Neuropathy: Abstract and Introduction
- Medscape, 4/22/10
-
Metformin may prevent lung cancer in smokers, early research suggests -
Science Daily, 4/19/10
-
Insulin
used to treat diabetes may be linked to increased cancer risk, review suggests
- Science Daily, 3/2/10 - "Research suggests that
metformin, which is used to treat some patients with diabetes, may provide a
protective effect, while insulin and/or certain insulin analogues may promote
tumour growth ... Diabetic patients were 30 per cent more likely to develop
colorectal cancer ... Women with diabetes had a 20 per cent greater risk of
developing breast cancer ... People with diabetes had an 82 per cent higher risk
of developing pancreatic cancer" - Note: See my
Insulin and Aging page. I think it's
like what came first the chicken or the egg. I don't believe they know
whether it's the insulin or the high blood sugar. This seems to support
that it's the high insulin.
-
Diabetes Drug Metformin Has Fishy Odor - WebMD, 2/16/10
-
Metformin May Help Obese Teens Lose Weight - WebMD, 2/1/10
-
Metformin is safe for patients with advanced heart failure and diabetes
mellitus, study shows - Science Daily, 1/7/10 - "The
study results suggest that, in patients with both advanced heart failure and
diabetes, use of metformin is safe, and may be associated with better heart
failure survival"
-
Click
here of a 10/5/09 news clip (I put it on YouTube) that claims that metformin
may provide the same anti-aging benefits as calorie restriction (you won't need
to look like a POW). Metformin is another one I take for anti-aging.
In addition to the calorie restriction type benefits, see my
Insulin and Aging page.
-
Metformin vs. Sulfonylureas for Diabetes - WebMD, 12/4/09 -
"Researchers reported that diabetes patients who used
sulfonylureas had a higher risk of death from all causes and a higher risk of
heart failure than diabetes patients who used the most widely prescribed
diabetes drug, metformin ... Compared with metformin, also known as Glucophage,
single-drug treatment with first- and second-generation sulfonylureas was
associated with up to a 61% increased risk for death. Users of second-generation
sulfonylureas had up to a 30% higher risk for congestive heart failure ...
Patients treated with Actos or Avandia did not appear to have a greater risk for
heart attacks than those treated with metformin"
-
Metformin Lowers Serum TSH
Levels in Diabetics With Hypothyroidism - Medscape, 10/2/09
-
Diabetes Drug Fights Breast Cancer - WebMD, 9/14/09 -
"And in mice carrying human breast cancers, metformin
made standard chemotherapy vastly more effective. Mice treated with the
combination remain cancer-free for four months, unlike mice treated with either
drug alone ... A lot of data shows lower cancer risk -- not just breast cancer
-- in people taking metformin for diabetes ... This drug at low doses can be
considered a very good candidate for cancer prevention before a person has any
cancer at all" - Note: I've been taking metformin for years for
anti-aging. See my Insulin and Aging page.
-
Metformin Linked to B12 Deficiency - WebMD, 6/8/09 -
"40% of type 2 diabetes patients using metformin had
vitamin B12 deficiency or were in the low-normal range for the essential
vitamin. And 77% of metformin users with vitamin B12 deficiency also had
peripheral neuropathy, a common form of nerve damage associated with type 2
diabetes" - See
B-12 products at iHerb
.
-
Common Diabetes Drug May 'Revolutionize' Cancer Therapies: Unexpected T-cell
Breakthrough - Science Daily, 6/4/09 - "We used
metformin, which is known to operate on fatty-acid metabolism, to enhance
this process, and have shown experimentally in mice that metformin increases
T-cell memory as well as the ensuing protective immunity of an experimental
anti-cancer vaccine"
-
'Cancer hope' from diabetes drug - BBC News, 6/3/09 -
"Tests on mice found metformin, used for Type 2
diabetes, helps the body's T-cells work more effectively"
-
Old
Diabetes Drug Teaches Experts New Tricks - Science Daily, 5/20/09
-
Metformin May Have Long-Term Benefits in Patients With Type 2 Diabetes -
Medscape, 4/10/09 - "Compared with the placebo
group, the metformin group had prevention of weight gain (mean weight gain,
−3.07 kg; range, −3.85 to −2.28 kg; P < .001), better glycemic control (mean
reduction in glycated hemoglobin level, 0.4%; 95% confidence interval [CI],
0.55 – 0.25; P < .001), and lower insulin requirements (mean reduction,
19.63 U/day; 95% CI, 24.91 – 14.36 U/day; P < .001) ... Add-on metformin
improved glycemic control and reduced body weight and insulin requirements"
-
Do Diabetes Drugs Affect Heart Health? - WebMD, 10/27/08 -
"metformin seemed to be associated with a decrease
in heart disease and heart-related deaths ... researchers point to metformin
as a drug that is "moderately protective" and Avandia as "possibly harmful."
... Avandia, which works well to reduce blood sugar, was associated with a
higher risk of heart attack. However, researchers in that case also
acknowledged that their conclusions were limited by a lack of access to
original clinical data"
-
Metformin May Enhance Weight Loss in Female Adolescents - Medscape,
7/8/08 - "a significant decrease in body mass index
was seen in females receiving metformin but not in those taking placebo.
Sixty percent of participants who were metformin-adherent and who decreased
food portion sizes had a decrease in body mass index of more than 5%"
- See
metformin
at OffshoreRx.com.
-
Metformin Increases Pathologic Complete Response Rates In Breast Cancer
Patients With Diabetes - Science Daily, 6/2/08 -
"the pathologic complete response rates in the diabetic breast cancer
patients taking Metformin was 24 percent, three times higher than the rates
in diabetic patients not taking the drug, 8 percent. In the non-diabetic
women, the pathologic complete response rate was 16 percent"
-
Metformin May Up
Alzheimer's Protein if Used Alone - Medscape, 10/15/09 -
"I think Chen's study is very important and
strengthens the concept of diabetes medication effects on Alzheimer's
neuropathology, but at this point I do not think that there is clinical
evidence for clinicians to be concerned when treating their diabetic
patients with metformin"
-
Metformin Alone or With
Insulin May Be Safe in Gestational Diabetes - Medscape, 5/7/08
-
No Benefits Seen With Metformin for Insulin Resistance in Obese Children:
Presented at ECE - Doctor's Guide, 5/7/08
-
Thiazolidinediones May Act Against Psoriasis - Medscape, 3/26/08 -
"The adjusted odds ratio for a first time diagnosis
of psoriasis in current users of five or more prescriptions for
thiazolidinediones was 0.33, as compared to no use. The adjusted odds ratio
for metformin was 0.77" - See pioglitazone at
OffshoreRX.com
.
-
Metformin May Delay Onset of Diabetes in At-Risk Subjects - Medscape,
3/24/08 - "Metformin treatment, compared with
placebo or no treatment, reduced body mass index by 5.3%, fasting glucose by
4.5%, fasting insulin by 14.4%, and calculated insulin resistance by 22.6%
... Metformin treatment also reduced triglycerides and LDL cholesterol by
5.3% and 5.6%, respectively, and increased HDL cholesterol by 5.0% ... The
incidence of new-onset diabetes was reduced by 40% (odds ratio, 0.6), with
an absolute risk reduction of 6%, during a mean trial duration of 1.8 years"
- I don't have diabetes yet still take 1,000 mg of metformin per day.
I still feel high blood sugar and advanced glycation end products are major
causes of aging. See
metformin
at OffshoreRx.com.
-
Insulin-Resistant
Cardiomyopathy - Medscape, 1/15/08 - "Increasing
evidence points to insulin resistance as a primary etiologic factor in the
development of nonischemic heart failure (HF) ... Epidemiological evidence
suggests more than simply a correlation between insulin resistance and HF,
demonstrating that insulin resistance precedes HF rather than occurring as a
consequence of it ... Medications that work primarily by improving insulin
sensitivity (metformin, thiazolidinediones [TZDs]) might theoretically be
the most attractive therapies" - See my web page on
Insulin and Aging.
-
Metformin, Lifestyle
Changes Effective in Antipsychotic-Induced Weight Gain - Medscape,
1/10/08 - "Lifestyle intervention plus metformin had
the greatest effect on weight loss, and metformin alone was more effective
than lifestyle intervention plus placebo in increasing insulin sensitivity
and reversing weight gain in these patients with schizophrenia and
significant weight gain from atypical antipsychotic agents"
-
Prevention of Type 2 diabetes: fact or fiction? - Expert Opin
Pharmacother. 2007 Dec;8(18):3147-58 - "The Diabetes
Prevention Program revealed that metformin 850 mg b.i.d. reduced the risk of
diabetes by 31%"
-
Drug May Help Pregnant Women with Insulin Resistance - Doctor's Guide,
9/6/07 - "metformin, the most commonly prescribed
anti-diabetes drug, could potentially improve pregnancy outcomes in women
with insulin resistance"
-
Diabetes Drug Kills Some Cancer Cells - Science Daily, 8/14/07 -
"Four weeks later, the p53-deficient tumors in mice
treated with metformin were half the size of the p53 deficient tumors in
control mice"
-
Older Is Better: Top Ten Comparison Of Diabetes Drugs Give Metformin Top
Grade - Science Daily, 7/25/07 - "Metformin was
found to lower LDL or bad cholesterol by about 10 milligrams per deciliter
of blood, while newer medications studied, such as pioglitazone (Actos) and
rosiglitazone (Avandia), or so-called thiazolidinediones, were found to have
the opposite effect, increasing levels of the artery-clogging fat by the
same amount"
-
Old Diabetes Drug Has Advantages - WebMD, 7/16/07
- The
Role of Metformin and Pioglitazone in Early Combination Treatment -
Medscape, 2/6/07 - "Both metformin and
pioglitazone have positive effects on cardiovascular risk factors. Pioglitazone
may reduce the progression to type 2 diabetes by effects on both pancreatic
beta-cell deterioration and insulin resistance"
-
Diabetes Drugs
Compared - WebMD, 12/6/06 - "Avandia had the lowest treatment failure rate -- 15% -- compared with 21%
for Glucophage and 34% for Micronase"
-
Drug 'Avandia' May Prevent Diabetes - WebMD, 9/15/06 -
"People at high risk for diabetes
who took the drug Avandia reduced
their risk of developing the disease by 60% in the three-year trial ...
taking the drug metformin (Glucophage), which is already widely used for
diabetes prevention, was associated with a 31% reduction in disease risk --
about half that seen in the Avandia study"
-
New EASD/ADA Consensus Recommends Metformin at Diagnosis of Type 2 Diabetes
- Doctor's Guide, 9/13/06 - "metformin
significantly reduced the risk of fatal and non-fatal cardiovascular events in
patients with type 2 diabetes(3). The study showed a 36% reduction in all-cause
mortality, a 42% reduction in diabetes-related mortality and a 32% reduction in
diabetes-related endpoints"
-
FDA
Approves Avandamet (Rosiglitazone Maleate and Metformin HCl) as Initial
Therapy in the Treatment of Type 2 Diabetes - Doctor's Guide, 7/11/06
-
Metformin Induces Long-Term Weight Loss in Teens - Doctor's Guide, 6/28/06 -
"Metformin can induce long-term weight
loss in obese, non-diabetic adolescents, and could possibly be useful in a
regimen to help achieve weight loss in adolescents, who may have developed type
2 diabetes type due to overweight"
-
Depression Drugs
May Up Diabetes Risk - WebMD, 6/12/06 -
"taking antidepressants was
associated with a two- to threefold increase in risk ... The increase was
not seen, however, in people at high risk for diabetes who were taking both
antidepressants and the blood-sugar-regulating drug glucophage (metformin)"
- Can
Metformin Help Teenagers With PCO? - Medscape, 4/19/06
-
Metformin and Lifestyle Intervention May Help Prevent Metabolic Syndrome
- Medscape, 4/18/06 - "Participants
were randomly assigned to standard treatment with placebo pill; metformin,
850 mg, twice daily; or intensive lifestyle management with placebo pill and
followed up for a mean of 3.2 years ... Intensive lifestyle consisted of
reduction of at least 7% of body weight, low-calorie and low-fat diet, and
moderate physical activity at least 150 minutes weekly ... In those with
prevalent MS at baseline ... At 3 years 18% of the placebo, 23% of the
metformin, and 38% of the lifestyle intervention group no longer had the MS,
with lifestyle intervention only showing a significant effect vs placebo"
-
Newer
Diabetic Meds Cost More, But Users Have Fewer Hospital Visits - Science
Daily, 3/24/06 - "Taking a TZD as
instructed was the strongest predictor of a reduced risk of hospitalization and
decreased healthcare costs in this group of patients ... Overall, the
participants who took a TZD spent an average of $76 to $150 less per month
on total healthcare costs" - See
OffshoreRx.com.
-
Metformin-Associated Lactic Acidosis Can Be Aggravated by Antihypertensive
Drugs in Diabetics - Doctor's Guide, 11/14/05 -
"Concurrent use of
angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor
blockers (ARBs) and metformin could aggravate the risk of
metformin-associated lactic acidosis"
-
Metformin Increases Ovulation in Women with Polycystic Ovary Syndrome Better
than Clomiphene Citrate - Doctor's Guide, 10/21/05
-
Metformin May Be Safer Than Sulfonylureas in Patients With Diabetes and
Heart Failure - Medscape, 9/30/05
-
ACTOplus Met Approved by the FDA for Type 2 Diabetes - Doctor's Guide,
8/30/05 - "ACTOplus met combines
ACTOS (pioglitazone HCl) and metformin, two widely used diabetes
medications, in a single tablet"
-
Review: Metformin a Top Diabetes Drug - WebMD, 7/19/05 -
"Though many of the newer drugs may
promote weight gain, metformin has been associated with modest weight losses
in people with type 2 diabetes"
-
Metformin Works Well as Monotherapy in Type 2 Diabetes Especially in
Overweight or Obese Patients - Doctor's Guide, 7/15/05
-
Metformin May Be Best First-Line Therapy for Anovulatory Women With
Polycystic Ovary Syndrome - Medscape, 4/29/05
-
Metformin and Lifestyle Intervention May Help Prevent Metabolic Syndrome
- Medscape, 4/18/05 - "metformin
therapy (850 mg twice daily) ... Compared with placebo, the lifestyle group
had 41% lower incidence of the MS (P < .001), and the metformin group had
17% lower incidence"
- Vitamin B12 Status of Patients Treated With Metformin - Medscape, 2/17/05 -
"Patients exposed to long-term metformin therapy had 26.7% lower cobalamin, 21.6% lower holotranscobalamin and 9.7% higher HCy
serum concentrations than control subjects. Such changes indicate a potential risk for development of vitamin B12 deficiency"
- Pioglitazone and Metformin Similarly Effective in Reducing HbA1c - Medscape, 12/13/04
- Research Highlights Hormonal Control of Cardiovascular Functions - Doctor's Guide, 8/17/04 -
"The Patients who received
metformin experienced an improvement in several endothelial function markers, including weight, fasting plasma glucose, soluble intercellular adhesion molecule and soluble vascular cell adhesion molecule"
- Metformin Shows Promise for Diabetes Prevention, but Further Studies Needed - Doctor's Guide, 6/24/04 -
"After 1 year of treatment, patients
receiving metformin experienced a significantly lower increase in fasting blood glucose levels compared with the placebo group (3.6 mg/dL vs. 7.2 mg/dL,
P < .05)"
- Metformin Can Prevent Girls with Insulin Resistance from Developing Polycystic Ovary Syndrome - Doctor's Guide, 6/21/04 -
"Early use of metformin in girls with insulin resistance can decrease the progression to polycystic ovary syndrome (PCOS), a common female endocrine disorder"
- Metformin, Diet/Exercise Comparable at Cutting Diabetes Risk in Women With GDM - Medscape, 6/7/04 -
"in women who reported a history of GDM, either metformin or lifestyle changes reduced the relative risk of later type 2 DM by about 54%. In contrast, the relative risk reduction associated with metformin was 14% in women with no history of GDM compared with 51% for lifestyle changes"
- Metformin May Improve Cardiac Autonomic System Balance in Overweight Patients with Type 2 Diabetes - Doctor's Guide, 3/15/04
- Metformin Improves Metabolic Control and Other Physiologic Variables in Type 2 Diabetes - Doctor's Guide, 2/25/04
-
What
You Don’t Know About Blood Sugar - Life Extension Magazine, 1/04 -
"it now appears that optimal fasting blood glucose levels should probably be under 86 mg/dL ... Chromium supplements have been shown to reduce blood glucose significantly.70-74
The dose used in human studies ranges from 200 to 1000 mcg of elemental chromium a day, with best results occurring when 400 mcg or more of chromium is taken daily ... Nondiabetics using metformin may start off at 500 mg a day and gradually build up to 1000-1500 mg a day. The objective is not to take so much
metformin as to induce a hypoglycemic state" - See
iHerb
or
Vitacost
chromium products.
- Metformin and Carbohydrate-Modified Diet May Help Sustain Weight Loss - Doctor's Guide, 12/16/03
- No Apparent Increased Risk of Lactic Acidosis Found In Type 2 Diabetics Who Take Metformin - Doctor's Guide, 11/25/03
- Metformin May Improve Metabolic Control in Adolescents with Type I Diabetes - Doctor's Guide, 11/21/03
- Metformin Decreases Serum C-Reactive Protein in Women With Polycystic Ovarian Syndrome - Doctor's Guide, 10/28/03
- Metformin Seems to be Effective for Anovulation in Women with Polycystic Ovary Syndrome - Doctor's Guide, 10/27/03
- Metformin Treatment Leads to Increased Homocysteine, Decreased Vitamin B12 and Folate in Type 2 Diabetes Patients - Doctor's Guide, 10/20/03 -
"Homocysteine requires folate and vitamin B12 to be properly metabolised, and serum vitamin B12 levels are known to decrease during metformin treatment ... compared with placebo, metformin was associated with an increase in
serum homocysteine levels (4% [0.2 to 8 µmol L-1]; P=0.039), and decreases in vitamin B12 (-14% [-4.2 to -24 pmol L-1]; P<0.0001) and folate (-7%"
- Uses of Metformin May Extend Beyond Patients with Type 2 Diabetes - Doctor's Guide, 9/4/03 -
"In type 2 diabetics, metformin appears to decrease
plasma fasting glucose and HbA1c levels without causing weight gain. Metformin may also have a positive influence on a variety of cardiovascular risk factors and may be useful in preventing diabetes in overweight individuals with mild hyperglycaemia ... while
further study is necessary before more widespread use is encouraged, the role of metformin may be expanded for glucose control in children and teenagers with type 2 diabetes, in non-diabetic women with PCOS, and to prevent progression to diabetes"
- FDA Approves New Avandamet (Rosiglitazone Maleate/Metformin) Dosage Strengths For Treatment Of Type 2 Diabetes - Doctor's Guide, 8/27/03
- Lifestyle Modification, Metformin Effective Prevention for Type 2 Diabetes - Doctor's Guide, 7/31/03 -
"1,073 patients were prescribed 850 mg
metformin twice daily, 1,082 had placebo twice daily, and 1,079 were prescribed an intensive program of lifestyle modification ... Incidence of diabetes was 58% lower ... in the lifestyle intervention group and 31% lower ... in the metformin group than in the placebo group"
- Inappropriate Metformin Use Frequent in Hospitalised Patients - Doctor's Guide, 6/16/03
-
BioMarker
Pharmaceuticals Develops Anti-Aging Therapy - LE Magazine cover story, 6/03 -
"The BioMarker scientists found that all the glucoregulatory agents reproduced some of the gene expression effects of CR [calorie restriction], but that metformin was the undisputed star of the group, being twice as effective as the others in
reproducing the effects of CR"
- Pioglitazone/Sulfonylurea And Pioglitazone/Metaformin Combinations Both Effective For Reducing Very Low Density Lipoproteins And Free Fatty Acids - Doctor's Guide, 5/21/03
- Repaglinide + Metformin Superior to Nateglinide + Metformin in Treating Type 2 Diabetes - Doctor's Guide, 5/18/03
- Benfluorex Improves Glycaemic Control In Type 2 Diabetes - Doctor's Guide, 4/29/03 -
"Although
benfluorex may be less potent than metformin, it lowers haemoglobin A1C (HbA1C) and fasting plasma glucose levels and is well tolerated"
- Metformin-Glibenclamide Combination Is More Effective Than Monotherapy In Type 2 Diabetes - Doctor's Guide, 4/24/03
- Pioglitazone Improves Insulin Sensitivity Compared To Metformin - Doctor's Guide, 4/22/03
- Combination Therapy Improves Management of Obese Diabetics - Doctor's Guide, 4/15/03 -
"Adding
rosiglitazone, an insulin-sensitising thiazolidinedione drug, to metformin, a biguanide agent, greatly enhances the management of obese type 2 diabetic patients who are inadequately controlled by metformin alone"
- Metformin Concentrations In Erythrocytes Have Clinical Implications - Doctor's Guide, 3/25/03
- Diabetes Prevention Efforts Achieving Good Results - Doctor's Guide, 2/17/03 -
"Strategies that may prevent progression to
diabetes include weight reduction, exercise, insulin secretagogues, metformin, glucosidase inhibitors and
thiazolidinedione ... Diabetes risk was reduced by 31% among patients who were treated with metformin (which tends to restrain weight gain) and by 58% for patients who improved their lifestyle ... Losing even 5 to 7 kg [11 to 15.4 pounds] "has an
enormous benefit" that was also apparent in cholesterol and other cardiovascular risk factor reductions"
- Glyburide/Metformin Combination Effective For Type 2 Diabetes Inadequately Controlled By Sulphonylurea - Doctor's Guide, 2/3/02
- Rosiglitazone And Metformin Have Different Effects In Diabetics - Doctor's Guide, 1/29/03
- Metformin May Help Teen Type 1 Diabetics - WebMD, 1/17/03
- Metformin May Benefit Type 1 Teen Diabetics - Medscape, 1/14/03
- Tablet Combining Glibenclamide And Metformin Improves Glycaemic Control - Doctor's Guide, 12/7/02
- Bristol-Myers Squibb Receives FDA Approval Of Metaglip (Glipizide/ Metformin HCl Tablets) For Type 2 Diabetes - Doctor's Guide, 10/22/02
- FDA Approves GlaxoSmithKline's Avandamet™ (rosiglitazone maleate and metformin HCl), The Latest Advancement in the Treatment of Type 2 Diabetes - Doctor's Guide, 10/11/02
- FDA Approves New Indication for Glucovance® (Glyburide and Metformin HCL Tablets) A Leading Oral Antidiabetic Now Approved for Use With TZDs - Doctor's Guide, 10/11/02
- Insulin-Lowering Agent [metformin] Curbs Hyperandrogenism And Polycystic Ovary Syndrome Symptoms - Doctor's Guide, 10/11/02
- Anti-Hyperglycemic Metformin Equally Effective in Extended-Release and Immediate-Release Formulations - Doctor's Guide, 9/26/02
- Extended-Release Metformin Formulation Shows Promise as Once Daily Regimen - Doctor's Guide, 9/25/02
- What is hyperinsulimia? How is it controlled? What are the tests? What is Glucophage? - Dr. Weil, 9/3/02 - "If
you take Glucophage, your physician should also monitor your liver function regularly and check blood counts and vitamin B12 levels"
- Single-Tablet Metformin-Glibenclamide Provides Type 2 Diabetics Better Glycaemic Control Than Either Drug Alone - Doctor's Guide, 8/28/02
- Metformin Therapy Lowers Plasma Levels Of Enzyme Linked To Endothelial Dysfunction In Type 2 Diabetics - Doctor's Guide, 7/24/02
- Combined Insulin Glargine and Metformin Therapy Treats Obese Type 2 Diabetics - Doctor's Guide, 6/18/02
- Metformin Useful in Teens with Poorly Controlled Type 1 Diabetes - Doctor's Guide, 6/18/02
- Metformin Decreases Cardiovascular Events in Diabetics - Doctor's Guide, 6/18/02
- Rosiglitazone Added to Glyburide/Metformin Helps Tough-to-Treat Diabetics - Doctor's Guide, 6/16/02
- Will New Drugs Head Off Diabetes? - WebMD, 5/10/02 -
""We think of IGT [impaired
glucose tolerance] and diabetes as parts of what we call the metabolic syndrome. This is something that affects one in four Americans -- and up to half of the U.S. population by age 60. What we have to target is high blood sugar, whether it is IGT or type 2 diabetes." ... One diabetes drug, Glucophage, has already been shown to help prevent type 2 diabetes in people with IGT.
But that same study, published in the February 2002 issue of The New England Journal of Medicine, showed that exercise was even better than Glucophage at preventing diabetes"
- Complementary Effects of Avandia and Metformin Significantly Improved Glycemic Control in High-Risk Diabetes Patients - Doctor's Guide, 4/30/02
- Troglitazone Improves Cardiovascular Risk Factors Better Than Metformin In Type 2 Diabetes - Doctor's Guide, 3/11/02 - See
troglitazone
- Diabetes Drug [Glucophage] Helps Prevent Miscarriage - WebMD, 3/1/02
- Metformin Shows Promise in Preventing Miscarriage in Polycystic Ovary Syndrome - Doctor's Guide, 2/27/02
- The Skinny on Fat Drugs - WebMD, 2/20/02 -
"This diabetes drug improves sensitivity to insulin. It seems to prevent weight gain in adults. Studies are
under way in overweight people who do not have diabetes. Side effects of Glucophage include nausea, flatulence, bloating, and diarrhea at the beginning of treatment. It can also cause a serious problem -- lactic acidosis -- in some patients with underlying disease"
- How to Stop Diabetes In Its Tracks - WebMD, 2/6/02 -
"the study found that the diet/exercise program cut diabetes risk by 58%. Glucophage was significantly less effective, but
still decreased risk by 31% ... The diet was centered around lowering fat intake to less than 25% of overall calories ... the 30-minute daily exercise regime "should be easily achievable" by most nondiabetic
overweight Americans with high blood sugar levels"
- Metformin Appears Suitable For Children With Type 2 Diabetes - Doctor's Guide, 1/18/02
- Diabetes Drug [Glucophage/metformin] May Fight Obesity - WebMD, 12/26/01 -
"Pediatricians at the University of Tennessee School of Medicine put 24 obese adolescents on a
low-calorie diet: 1,500 calories a day for the girls and 1,800 calories a day for the boys. They also gave half the teens Glucophage and half a placebo ... After eight weeks, dieting teens who took the placebo lost 3.8 % of
their body weight. But those taking Glucophage lost 6.5 % of their body weight -- nearly twice as much"
- Metformin-Glibenclamide Combo Manages Total Glycemic Burden In Type 2 Diabetes - Doctor's Guide, 9/17/01
- Repaglinide Plus Metformin Increases Insulin Secretion And Sensitivity In Type 2 Diabetics - Doctor's Guide, 9/13/01
-
The
Multiple Benefits of Metformin - Life Extension Magazine, 9/01 -
"An ideal anti-diabetic drug would enhance cellular insulin sensitivity, inhibit excess intestinal absorption of sugar, reduce excess liver production of glucose, promote weight loss and reduce cardiovascular
risk factors. Metformin (Glucophage) is the one drug that does all of this and more"
- Diet and Exercise, Metformin, Dramatically Delay Type 2 Diabetes - Doctor's Guide, 8/8/01
- How to Avoid Diabetes -- Landmark Results Unveiled - WebMD, 8/8/01 -
"Either a low-fat diet combined with moderate exercise or the drug metformin -- brand name Glucophage --
dramatically reduced type 2 diabetes risk among overweight people with elevated blood sugar"
- Glyburide/Metformin Combination Helps Maintain Long-Term Blood Sugar Control - Doctor's Guide, 6/26/01
- Metformin Outperforms Other Oral Agents In Diabetics With Severe Coronary Disease - Doctor's Guide, 3/22/01
- Nateglinide Appears To Reduce HbA(1c) Comparable to Metformin - Doctor's Guide, 11/17/00
- FDA Approves Glucophage XR (Metformin) Extended Release Formulation For Type 2 Diabetes - Doctor's Guide, 10/16/00
- FDA Approves Glucovance (Glyburide And Metformin) For Type 2 Diabetes - Doctor's Guide, 8/2/00
- Diabetes Drug, Metformin, May Be Useful In Treating AIDS-Related Syndrome - Doctor's Guide, 7/25/00
- Metformin Safe And Effective For Children With Type 2 Diabetes - Doctor's Guide, 6/12/00
- Avandia (Rosiglitazone) And Glucophage (Metformin) Combo May Slow Type 2 Diabetes Progression - Doctor's Guide, 4/5/00
- Controversy Remains Over Sulfonylurea-Metformin Combination Therapy - Doctor's Guide, 10/1/99
- Doctors Prescribing Metformin Despite Clear Contraindications - Doctor's Guide, 9/30/99
- Glucophage Reduces Deaths In Type II Diabetics, Study Shows - Doctor's Guide, 9/11/98
Abstracts:
-
Pioglitazone
may accelerate disease course of slowly progressive type 1 diabetes -
Diabetes Metab Res Rev. 2011 Nov;27(8):951-3 - "The
enrolled SPIDDM patients were randomly allocated to a pioglitazone or metformin
group. When the haemoglobin A1C level was more than 8% on two consecutive
occasions, the case was considered to reach the end point ... By 4 years
post-intervention, all patients had reached the end point in the pioglitazone
group, whereas only 20% of patients had reached the end point in the metformin
group"
-
Reduced Risk
of Colorectal Cancer With Metformin Therapy in Patients With Type 2 Diabetes: A
meta-analysis - Diabetes Care. 2011 Oct;34(10):2323-8 -
"Both in vitro and
in vivo studies indicate that metformin inhibits cancer cell growth and reduces
cancer risk ... The analysis included five studies comprising 108,161 patients
with type 2 diabetes. Metformin treatment was associated with a significantly
lower risk of colorectal neoplasm (relative risk [RR] 0.63 [95% CI 0.50-0.79]; P
< 0.001). After exclusion of one study that investigated colorectal adenoma, the
remaining four studies comprised 107,961 diabetic patients and 589 incident
colorectal cancer cases during follow-up. Metformin treatment was associated
with a significantly lower risk of colorectal cancer (0.63 [0.47-0.84]; P =
0.002)"
-
The effects
of metformin on the survival of colorectal cancer patients with diabetes
mellitus - Int J Cancer. 2011 Sep 12 - "Metformin
use has been associated with decreased cancer risk and mortality ... We
identified 595 patients who were diagnosed both CRC and diabetes mellitus.
Patients were compared by two groups; 258 diabetic patients taking metformin and
337 diabetic patients not taking metformin ... After a median follow-up of 41
months, there were 71 total deaths (27.5%) and 55 CRC-specific deaths (21.3%)
among 258 patients who used metformin, compared with 136 total deaths (40.4%)
and 104 CRC-specific deaths (30.9%) among 337 patients who did not use
metformin. Metformin use was associated with decreased overall mortality
(P=0.018) and CRC-specific mortality (P=0.042) by univariate analysis. After
adjustment for clinically relevant factors, metformin use showed lower risk of
overall mortality (HR, 1.45; 95% CI, 1.084-1.934; P=0.016) and CRC-specific
mortality (HR, 1.44; 95% CI, 1.026-2.061; P=0.035) in CRC patients with
diabetes. Metformin use in CRC patients with diabetes is associated with lower
risk of CRC-specific and overall mortality"
-
Cancer
mortality reduction and metformin. A retrospective cohort study in type 2
diabetic patients - Diabetes Obes Metab. 2011 Aug -
"All-cause and cancer-related deaths occurred in: 9.2%, 1.6% of metformin users,
13.1%, 3.0% of sulfonylureas users and 26.8%, 4.8%of insulin users,
respectively. In a Cox regression model for competing risks, adjusted for
propensity score, metformin users showed a lower cancer mortality risk
(HR=0.56;95%CI 0.34-0.94), while insulin was positively associated with
other-than-cancer-mortality (HR=1.56; 1.22-1.99). Each 5-year metformin exposure
was associated with a reduction in cancer death by 0.73, whereas every 5-year
insulin exposure was associated with 1.25-fold increase in other-than-cancer
death. Standardized mortality ratios for cancer and other-than-cancer mortality
in metformin users were 43.6 (95%CI 25.8-69.0) and 99.1 (79.3-122.5)
respectively, in comparison with the general population. Conclusions: Metformin
users showed a lower risk of cancer-related mortality than not users or patients
on diet only; this may represent another reason to choose metformin as a
first-line therapy in T2DP"
-
Effects of
pioglitazone vs metformin on circulating endothelial microparticles and
progenitor cells in patients with newly diagnosed type 2 diabetes - a randomized
controlled trial - Diabetes Obes Metab. 2011 Jan 21 -
"Participants assigned to pioglitazone gained more
weight and experienced greater improvements in some coronary risk measures
(HDL-cholesterol, triglycerides, adiponectin, and C-reactive protein) than did
those assigned to metformin. Conclusion: Compared with metformin, pioglitazone
treatment improved the imbalance between endothelial damage and repair capacity,
and led to more favorable changes in coronary risk factors in patients with
newly-diagnosed type 2 diabetes"
-
Effects
of Metformin on Body Weight and Body Composition in Obese Insulin-Resistant
Children: A Randomized Clinical Trial - Diabetes. 2011 Jan 12 -
"1,000 mg
metformin (n = 53) or placebo (n = 47) twice daily for 6 months ...Children
prescribed metformin had significantly greater decreases in BMI (difference
-1.09 kg/m(2), CI -1.87 to -0.31, P = 0.006), body weight (difference -3.38 kg,
CI -5.2 to -1.57, P < 0.001), BMI Z score (difference between metformin and
placebo groups -0.07, CI -0.12 to -0.01, P = 0.02), and fat mass (difference
-1.40 kg, CI -2.74 to -0.06, P = 0.04). Fasting plasma glucose (P = 0.007) and
homeostasis model assessment (HOMA) insulin resistance index (P = 0.006) also
improved more in metformin-treated children than in placebo-treated children.
Gastrointestinal symptoms were significantly more prevalent in metformin-treated
children, which limited maximal tolerated dosage in 17%. During the 6-month
open-label phase, children treated previously with placebo decreased their BMI Z
score; those treated continuously with metformin did not significantly change
BMI Z score further. CONCLUSIONS Metformin had modest but favorable effects on
body weight, body composition, and glucose homeostasis in obese
insulin-resistant children participating in a low-intensity weight-reduction
program" - Note: 3.38 kg equals 7.4 pounds.
-
Metformin
Treatment Exerts Antiinvasive and Antimetastatic Effects in Human Endometrial
Carcinoma Cells - J Clin Endocrinol Metab. 2010 Dec 29 -
"In vitro invasion in ECC-1 cells was significantly
attenuated by sera from PCOS women after 6 months of metformin treatment (850 mg
twice daily) compared to matched controls (P < 0.01). These effects appear to be
associated with NF-κB, MMP-2/9, as well as Akt and Erk1/2 pathways that are
known to be important regulators of inflammation, tumor invasion and metastasis.
Conclusions: Metformin, potentially, may serve as adjuvant treatment in the
management of patients with endometrial cancer"
-
Metformin
and incident breast cancer among diabetic women: a population-based case-control
study in Denmark - Cancer Epidemiol Biomarkers Prev. 2010 Nov 30 -
"Metformin users were less likely to be diagnosed with
breast cancer (OR=0.77; 95% CI=0.61, 0.99) than non-metformin users. Adjusting
for diabetes complications, clinically diagnosed obesity, and important
predictors of breast cancer did not substantially alter the association
(OR=0.81; 95%CI=0.63, 0.96). CONCLUSION: Our results suggest that metformin may
protect against breast cancer in type 2 diabetic peri- or postmenopausal women.
Impact: This study supports the growing evidence of a role for metformin in
breast cancer chemoprevention"
-
Effects of
pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk
markers of inflammation and lipid profile compared with pioglitazone and
metformin monotherapy in patients with type 2 diabetes - J Clin Hypertens
(Greenwich). 2010 Dec;12(12):973-82 - "fixed-dose
combination (FDC) of pioglitazone/metformin compared with the respective
monotherapies ... FDC and pioglitazone increased high-density lipoprotein
cholesterol by 14.20% and 9.88%, respectively, vs an increase of 6.09% with
metformin (P<.05, metformin vs FDC). Triglycerides decreased with all three
treatments -5.95%, -5.54% and -1.78%, respectively; P=not significant). FDC and
pioglitazone significantly decreased small low-density lipoprotein and increased
large low-density lipoprotein particle concentrations. Reductions in
high-sensitivity C-reactive protein were greater in the FDC and pioglitazone
groups. Increases in adiponectin were significant in the FDC and pioglitazone
groups (P<.0001 vs metformin). Overall, adverse events were not higher with the
FDC. Thus, treatment with the FDC resulted in improved levels of CV biomarkers,
which were better than or equal to monotherapy"
-
Metformin
inhibits HMGB1 release in LPS-treated RAW 264.7 cells and increases survival
rate of endotoxaemic mice - Br J Pharmacol. 2010 Nov 22 -
"lipopolysaccharide (LPS)-treated animals and cells ...
metformin significantly attenuates the pro-inflammatory response induced by LPS
both in vivo and in vitro. Metformin improved survival in a mouse model of
lethal endotoxaemia by inhibiting HMGB1 release. AMPK activation was implicated
as one of the mechanisms contributing to this inhibition of HMGB1 secretion"
-
Metformin
Use and Mortality Among Patients With Diabetes and Atherothrombosis - Arch
Intern Med. 2010 Nov 22;170(21):1892-1899 - "The mortality rates were 6.3% (95%
confidence interval [CI], 5.2%-7.4%) with metformin and 9.8% 8.4%-11.2%) without
metformin; the adjusted hazard ratio (HR) was 0.76 (0.65-0.89; P < .001).
Association with lower mortality was consistent among subgroups, noticeably in
patients with a history of congestive heart failure (HR, 0.69; 95% CI,
0.54-0.90; P = .006), patients older than 65 years (0.77; 0.62-0.95; P = .02),
and patients with an estimated creatinine clearance of 30 to 60 mL/min/1.73 m(2)
(0.64; 95% CI, 0.48-0.86; P = .003) (to convert creatinine clearance to mL/s/m(2),
multiply by 0.0167)"
-
Metformin
treatment is associated with a low risk of mortality in diabetic patients with
heart failure: a retrospective nationwide cohort study - Diabetologia. 2010
Sep 14 - "With sulfonylurea monotherapy used as the
reference, adjusted hazard ratios for all-cause mortality associated with the
different treatment groups were as follows: metformin 0.85 (95% CI 0.75-0.98,
p = 0.02), metformin + sulfonylurea 0.89 (95% CI 0.82-0.96, p = 0.003),
metformin + insulin 0.96 (95% CI 0.82-1.13, p = 0.6),
metformin + insulin + sulfonylurea 0.94 (95% CI 0.77-1.15, p = 0.5),
sulfonylurea + insulin 0.97 (95% CI 0.86-1.08, p = 0.5) and insulin 1.14 (95% CI
1.06-1.20, p = 0.0001)"
-
Metformin is
associated with improved left ventricular diastolic function measured by tissue
Doppler imaging in patients with diabetes - Eur J Endocrinol. 2010 Aug 2 -
"use of metformin was associated with a shorter IVRT
(parameter estimate -9.9 ms, p=0.049), and higher e' (parameter estimate +0.52
cm/s, p=0.03), compared to no use of metformin. The effects of metformin were
not altered by concomitant use of sulfonylureas or insulin (p for interactions
>0.4). Conclusions: Use of metformin is associated with improved left
ventricular relaxation, as compared with no use of metformin"
-
Long-term
metformin use is associated with decreased risk of breast cancer - Diabetes
Care. 2010 Mar 18 - "The mean age was 67.5 (+/-std 10.5) years at the time of
the cancer diagnosis. Long-term use of 40+ prescriptions (>5 years) of
metformin, based on 17 exposed cases and 120 exposed controls, was associated
with an adjusted OR of 0.44 (95% CI 0.24-0.82) for developing breast cancer, as
compared to no use of metformin"
-
Effects of
metformin with or without supplementation with folate on homocysteine levels and
vascular endothelium of women with polycystic ovary syndrome - Diabetes
Care. 2009 Nov 23 - "Metformin exerts a slight but
significant deleterious effect on serum Hcy levels in patients with PCOS, and
supplementation with folate is useful to increase the beneficial effect of
metformin on the vascular endothelium"
-
Metformin
associated with lower cancer mortality in type 2 diabetes (ZODIAC-16) -
Diabetes Care. 2009 Nov 16 - "Median follow-up time was
9.6 years, average age at baseline was 68 years, and average HbA1c was 7.5%.
Five hundred seventy patients died, of which 122 from malignancies. SMR for
cancer mortality was 1.47 (95%CI 1.22-1.76). In patients taking metformin
compared to patients not taking metformin at baseline, the adjusted hazard ratio
(HR) for cancer mortality was 0.43 (95%CI 0.23-0.80), and the HR with every
increase of 1 gram of metformin was 0.58 (95%CI 0.36-0.93) ... In general,
patients with type 2 diabetes are at increased risk for cancer mortality. In our
group, metformin use was associated with lower cancer mortality when compared to
non-metformin use. Although the design cannot be conclusive about causality, our
results suggest a protective effect of metformin on cancer mortality"
-
Many
Americans Have Prediabetes and Should Be Considered for Metformin Therapy -
Diabetes Care. 2009 Oct 6 - "Criteria for consideration
of metformin included the presence of both IFG and IGT, with >/=1 additional
diabetes risk factor: age <60 years, BMI >/=35 kg/m(2), family history of
diabetes, elevated triglycerides, reduced HDL-cholesterol, hypertension, or A1c
>6.0% ... To the extent that our findings are representative of the U.S.
population, approximately 1 in 12 adults has a combination of prediabetes and
risk factors which may justify consideration of metformin treatment for diabetes
prevention"
-
Metformin
use and prostate cancer in Caucasian men: results from a population-based
case-control study - Cancer Causes Control. 2009 Aug 4 -
"In Caucasian men, metformin use was more common in
controls than in cases (4.7 vs. 2.8%, p = 0.04), resulting in a 44% risk
reduction for PCa (adjusted OR = 0.56; 95% CI 0.32-1.00). No association was
seen in African-American men"
-
Effect of
adjunct metformin treatment on levels of plasma lipids in patients with type 1
diabetes - Diabetes Obes Metab. 2009 Jun 25 - "After
1 year, in those patients who did not start or stop statin therapy during the
trial, metformin treatment significantly reduced total and LDL cholesterol by
approximately 0.3 mmol/l compared with placebo (p = 0.021 and p = 0.018
respectively). Adjustment for statin use or known cardiovascular disease did not
change conclusions. In statin users (metformin: n = 22, placebo: n = 13),
metformin significantly lowered levels of LDL and non-HDL cholesterol by
approximately 0.5 mmol/l compared with placebo"
-
New users of
metformin are at low risk of incident cancer: A cohort study among people with
type 2 diabetes - Diabetes Care. 2009 Jun 29 -
"Activation of AMPK can suppress tumour formation and inhibit cell growth, in
addition to lowering blood glucose levels. We tested the hypothesis that
metformin reduces the risk of cancer in people with type 2 diabetes ... Cancer
was diagnosed among 7.3% of 4,085 metformin users compared with 11.6% of 4,085
comparators, with median times to cancer of 3.5 years and 2.6 years respectively
(p < 0.001). The unadjusted hazard ratio for cancer was 0.46 (0.40-0.53). After
adjusting for sex, age, BMI, HbA1c, deprivation, smoking and other drug use,
there was still a significantly reduced risk of cancer associated with
metformin: 0.63 (0.53-0.75)"
-
Metformin
restores impaired HDL-mediated cholesterol efflux due to glycation -
Atherosclerosis. 2009 Mar 19 - "In the presence of
metformin or aminoguanidine (100mM), glycated HDL-mediated cholesterol efflux
was restored to 97.5+/-4.3% and 96.9+/-3.1%, respectively"
-
Pioglitazone
Improves Cardiac Function and Alters Myocardial Substrate Metabolism Without
Affecting Cardiac Triglyceride Accumulation and High-Energy Phosphate Metabolism
in Patients With Well-Controlled Type 2 Diabetes Mellitus - Circulation.
2009 Apr 6 - "were assigned to pioglitazone (30 mg/d) or
metformin (2000 mg/d) and matching placebo for 24 weeks ... No patient developed
heart failure. Both therapies similarly improved glycemic control, whole-body
insulin sensitivity, and blood pressure. Pioglitazone versus metformin improved
the early peak flow rate (P=0.047) and left ventricular compliance. Pioglitazone
versus metformin increased myocardial glucose uptake (P<0.001), but
pioglitazone-related diastolic improvement was not associated with changes in
myocardial substrate metabolism. Metformin did not affect myocardial function
but decreased cardiac work relative to pioglitazone (P=0.006), a change that was
paralleled by a reduced myocardial glucose uptake and fatty acid oxidation.
Neither treatment affected cardiac high-energy phosphate metabolism or
triglyceride content. Only pioglitazone reduced hepatic triglyceride content"
- I still take pioglitazone even though I don't have diabetes because I feel
that higher glucose levels are a major cause of aging. There doesn't seem
to be any evidence that it has the heart rises that rosiglitazone has. See Pioglitazone at
OffshoreRX.com
.
-
Efficacy and
safety of therapy with metformin plus pioglitazone in the treatment of patients
with type 2 diabetes: a double-blind, placebo-controlled, clinical trial -
Curr Med Res Opin. 2009 Mar 23 - "Mean HbA(1c) was
reduced by 0.67% in patients receiving pioglitazone plus metformin versus an
increase of 0.25% in those receiving metformin alone (p < 0.0001). After 8
weeks' treatment and until the end of the study, HbA(1c) was significantly lower
with pioglitazone plus metformin and more patients in this group achieved an
HbA(1c) < 6.5% (38.6% vs. 8.1%; p < 0.0001). FBG was also reduced by a
significantly greater amount in patients receiving pioglitazone plus metformin
compared with metformin monotherapy (-20.5 vs. 1.9 mg/dl; p < 0.0001).
Combination therapy was associated with significantly increased HDL-cholesterol,
total cholesterol, and adiponectin, and significantly decreased levels of
fasting insulin, free fatty acids, and homeostasis model assessment insulin
resistance (HOMA-R) compared with metformin monotherapy" - See
pioglitazone at OffshoreRX.com.
-
Treatment of
white coat hypertension with metformin - Int Heart J. 2008 Nov;49(6):671-9 -
"White coat hypertension (WCH) is most likely a disorder
associated with metabolic syndrome ... Twenty-five cases (14.7%) stopped
metformin therapy due to excessive anorexia. At the end of a 6-month period,
there were highly significant differences between the two groups with respect to
the prevalences of resolved WCH, hyperbetalipoproteinemia, hypertriglyceridemia,
dyslipidemia, overweight and obesity, and decreased fasting plasma glucose below
110 mg/dL ... Thus, the management of WCH should not focus solely on the
regulation of blood pressure with antihypertensive medications, but rather on
the prevention of future excess weight and various associated disorders, and
metformin alone is an effective therapeutic option, most likely due to its
powerful inhibitory effect on appetite"
-
Effect of
Metformin-Containing Antidiabetic Regimens on All-cause Mortality in Veterans
With Type 2 Diabetes Mellitus - Am J Med Sci. 2008 Sep;336(3):241-7 -
"Treatment of T2DM with regimens containing metformin
alone or in combination with other hypoglycemic agents was associated with
reduced all-cause mortality compared with regimens without metformin"
-
The
effects of 8 months of metformin on circulating GGT and ALT levels in obese
women with polycystic ovarian syndrome - Int J Clin Pract. 2008 Jun 19 -
"treated with metformin 1500 or 2550 mg/day for 8 months
... Mean weight, serum ALT and GGT decreased from 100.3 to 96.6 kg (p < 0.0001),
29.7 to 25.8 U/l (p = 0.012) and 21.4 to 16.9 U/l (p < 0.0001) respectively ...
In women with baseline ALT > 29.7 U/l (median), ALT reduction was highly
significant (p = 0.005); however in those with baseline ALT < 29.7 U/l, ALT did
not change despite similar weight reduction. There was no difference in
reductions in ALT and GGT when the two metformin doses were compared"
-
Role of
Metformin for Weight Management in Patients Without Type 2 Diabetes (June) -
Ann Pharmacother. 2008 May 13 - "The weight loss effects of metformin in
overweight or obese adults and adolescents without diabetes appear promising;
however, trials have been limited by small patient populations and weak design.
Metformin may also have a positive effect on metabolic parameters such as waist
circumference, fasting insulin and glucose levels, and triglycerides" - See
metformin at at
OffshoreRx.com.
-
Metformin improves polycystic ovary syndrome symptoms irrespective of
pre-treatment insulin resistance - Eur J Endocrinol. 2007
Nov;157(5):669-76 - "In the overweight and obese
PCOS groups, metformin also showed the expected beneficial effects ...
Metformin improves parameters of IR, hyperandrogenemia, anovulation, and
acne in PCOS irrespective of pre-treatment IR or obesity"
-
Decreased in vivo oxidative stress and decreased platelet activation
following metformin treatment in newly diagnosed type 2 diabetic subjects
- Diabetes Metab Res Rev. 2007 Oct 30 - "These data
suggest that metformin could improve oxidative stress, preserve antioxidant
function and restrain platelet activation in type 2 diabetes"
-
Liver dysfunction in paediatric obesity: a randomized, controlled trial of
metformin - Acta Paediatr. 2007 Sep;96(9):1326-32 -
"In obese adolescents fed ad libitum, metformin (a)
prevented the rise in ALT concentrations that were observed in
placebo-treated subjects at the 3 to 5 month time-points (p < 0.05); (b)
reduced (p < 0.01) the percentage of all ALT values exceeding 40 U/L; and
(c) caused a modest (10%) but statistically significant (p < 0.05) reduction
in serum ALT in Caucasian subjects. Metformin had no effect on ALT levels or
the ALT to AST ratio in the five African American adolescents enrolled in
the study ... metformin might reduce the rates or severity of liver
dysfunction in selected high-risk adolescents"
-
Metformin as an adjunctive treatment to control body weight and metabolic
dysfunction during olanzapine administration: A multicentric, double-blind,
placebo-controlled trial - Schizophr Res. 2007 Jul;93(1-3):99-108 -
"Metformin may safely assist olanzapine-treated
patients in body weight and carbohydrate metabolism control"
-
Comparison of the effects of pioglitazone and metformin on insulin
resistance and hormonal markers in patients with impaired glucose tolerance
and early diabetes - Hypertens Res. 2007 Jan;30(1):23-30 -
"pioglitazone was superior to
metformin for the improvement of insulin resistance and adiponectin ...
Early intervention with pioglitazone or metformin therapy may reduce the
incidence of future cardiovascular disease in subjects with impaired glucose
tolerance or early diabetes"
-
Treating the metabolic syndrome - Expert Rev Cardiovasc Ther. 2007
May;5(3):491-506 - "appropriate
treatment of MS components often requires pharmacologic intervention with
insulin-sensitizing agents, such as metformin and
thiazolidinediones, while
statins and fibrates, or
angiotensin-converting
enzyme inhibitors and
angiotensin II receptor blockers are the first-line lipid-modifying or
antihypertensive drugs"
-
Rosiglitazone is more effective than metformin in improving fasting indexes
of glucose metabolism in severely obese, non-diabetic patients -
Diabetes Obes Metab. 2007 Mar 29 - "Our study shows that in severely obese, non-diabetic, hyperinsulinaemic
patients undergoing a nutritional programme, rosiglitazone is more effective
than metformin in producing favourable changes in fasting-based indexes of
glucose metabolism, with a reduction of both insulin resistance and
hyperinsulinaemia. In spite of previous studies reporting
rosiglitazone-induced body weight gain, in our study the joint treatment
with diet and rosiglitazone was accompanied by weight loss and fat mass
reduction"
-
Effects of metformin or rosiglitazone on serum concentrations of
homocysteine, folate, and vitamin B(12) in patients with type 2 diabetes
mellitus - J Diabetes Complications. 2007 Mar-Apr;21(2):118-23 -
"In patients with type 2 diabetes,
metformin reduces levels of folate and vitamin B(12) and increases Hcy.
Conversely, rosiglitazone decreases Hcy levels in this time period"
-
A randomized trial of the effects of rosiglitazone and metformin on
inflammation and subclinical atherosclerosis in patients with type 2
diabetes - Am Heart J. 2007 Mar;153(3):445.e1-6 -
"Metformin and rosiglitazone
treatment led to similar significant improvements in glycemic control
(HbA(1c) -1.08% in the rosiglitazone group and -1.18% in the metformin
group, P = nonsignificant). High-sensitivity C-reactive protein levels
decreased by an average of 68% in the rosiglitazone group (5.99 +/- 0.88 to
1.91 +/- 0.28 mg/L, P < .001), compared with a nonsignificant 4% reduction
in hsCRP with metformin"
-
Effects of rosiglitazone and metformin on inflammatory markers and
adipokines: decrease in interleukin-18 is an independent factor for the
improvement of homeostasis model assessment-beta in type 2 diabetes mellitus
- Clin Endocrinol (Oxf). 2007 Feb;66(2):282-9 - "Rosiglitazone, but not metformin,
improved the plasma concentrations of inflammatory markers and adipokines in
patients with type 2 diabetes mellitus"
-
Glycemic
Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy - N Engl J
Med. 2006 Dec 4- "Kaplan-Meier analysis showed
a cumulative incidence of monotherapy failure at 5 years of 15% with
rosiglitazone, 21% with metformin, and 34% with glyburide. This represents a
risk reduction of 32% for rosiglitazone, as compared with metformin, and 63%, as
compared with glyburide (P<0.001 for both comparisons). The difference in the
durability of the treatment effect was greater between rosiglitazone and
glyburide than between rosiglitazone and metformin. Glyburide was associated
with a lower risk of cardiovascular events (including congestive heart failure)
than was rosiglitazone (P<0.05), and the risk associated with metformin was
similar to that with rosiglitazone. Rosiglitazone was associated with more
weight gain and edema than either metformin or glyburide but with fewer
gastrointestinal events than metformin and with less hypoglycemia than
glyburide"
-
Effects of rosiglitazone and pioglitazone combined with metformin on the
prothrombotic state of patients with type 2 diabetes mellitus and metabolic
syndrome - J Int Med Res. 2006 Sep-Oct;34(5):545-55 -
"In patients with type 2 diabetes
mellitus and metabolic syndrome, the combination of metformin plus
thiazolidinediones improved glycaemic control and produced a slight but
significant reduction in plasminogen activator inhibitor-1 levels"
-
An open-label pilot study of the combination therapy of metformin and
fluoxetine for weight reduction - Int J Obes (Lond). 2006 Sep 12 -
"In a 6.68-month period, a 7.89 kg
decrease in weight (9.32%) and a 3.43 U decrease in BMI (10.14%) were
observed in participants of the case group that was statistically
significant"
-
Improvement in glycaemic control with rosiglitazone/metformin fixed-dose
combination therapy in patients with type 2 diabetes with very poor
glycaemic control - Diabetes Obes Metab. 2006 Nov;8(6):643-649 -
"Unless tolerability issues arose,
eligible patients initiated RSG/MET 4 mg/1000 mg fixed-dose combination
therapy and were up-titrated in increments of 2 mg/500 mg at 4-week
intervals to a daily dose of 8 mg/2000 mg or the maximum tolerated dose ...
At week 24, clinically significant mean reduction in A1c from 11.8 to 7.8%
(mean reduction, 4.0 +/- 2.2%; p < 0.0001) and mean FPG reduction from 16.9
to 9.2 mmol/l (mean reduction, 7.7 +/- 4.4 mmol/l; p < 0.0001) were
observed"
-
Risk factors of vitamin B12 deficiency in patients receiving metformin -
Arch Intern Med. 2006 Oct 9;166(18):1975-9 -
"Each 1-g/d metformin dose increment
conferred an odds ratio of 2.88 (95% confidence interval, 2.15-3.87) for
developing vitamin B(12) deficiency" - See
iHerb
or Vitacost Vitamin B12 products.
-
Adherence to Preventive Medications: Predictors and outcomes in the Diabetes
Prevention Program - Diabetes Care. 2006 Sep;29(9):1997-2002 -
"There was a 38.2% risk reduction
for developing diabetes for those adherent to metformin compared with those
adherent to placebo" - See metformin at OffshoreRX.com
or
SuperSaverMeds.com (Glucophage).
-
Metformin improves endothelial vascular reactivity in first-degree relatives
of type 2 diabetic patients with metabolic syndrome and normal glucose
tolerance - Diabetes Care. 2006 May;29(5):1083-9 -
"The metformin group had decreased
weight, BMI, systolic blood pressure, and FPG and improved lipid profile.
Endothelium-dependent FBF responses were also improved, without any effect
on endothelium-independent responses"
-
Currently listed contraindications to the use of metformin -
more harmful than beneficial? - Dtsch Med
Wochenschr. 2006 Jan 20;131(3):105-10 - "As the incidence of lactic acidosis
in patients with type 2 diabetes is the same with or without metformin
therapy (about 9 per 100000 patient years) there is no evidence that
metformin therapy is associated with an increased risk of lactic acidosis
... The two groups did not differ with regard to progression of renal
failure, patient-oriented endpoints or overall mortality ... On the basis of
the current data, advanced age per se, mild renal impairment and stable
heart failure can no longer be upheld as contraindications to the use of
metformin"
-
Metformin revisited: re-evaluation of its properties and role in the
pharmacopoeia of modern antidiabetic agents - Diabetes Obes Metab. 2005
Nov;7(6):654-65 - "Metformin acts by
increasing tissue sensitivity to insulin, principally in the liver.
Beneficial properties of metformin include weight reduction, favourable
effects on the lipid profile and the fibrinolytic pathway, and improvement
of ovarian function in some insulin-resistant women. It does not cause
hyperinsulinaemia or hypoglycaemia" - See
Glucophage at SuperSaverMeds.com or OffshoreRX.com
.
-
Metformin decelerates aging and development of mammary tumors in HER-2/neu
transgenic mice - Bull Exp Biol Med. 2005 Jun;139(6):721-3 -
"Mean life span of mice increased by
8% (p<0.05), in 10% long-living mice it was prolonged by 13.1%, and the
maximum life span was prolonged by 1 month under the effect of metformin in
comparison with the control. The rate of populational aging decreased by
2.26 times ... Hence, we first demonstrated a geroprotective effect of
metformin and its suppressive effect towards the development of mammary
tumors"
-
The impact of antidiabetic therapies on cardiovascular disease - Curr
Atheroscler Rep. 2005 Feb;7(1):50-7 - "Metformin is the only oral
antidiabetic medication shown to decrease cardiovascular events independent
of glycemic control. Thiazolidinediones improve insulin resistance and lower
insulin concentrations, which is beneficial because hyperinsulinemia is an
independent predictor of cardiovascular disease"
-
Metformin and weight loss in obese women with polycystic ovary syndrome
(PCOS): comparison of doses - J Clin Endocrinol Metab. 2005 May 10 -
"the Ob sub-group showed a dose
relationship (1.5 Kg [3.3 lbs] and 3.6 Kg [7.9 lbs] in 1500 mg and 2550 mg
groups respectively ... Suppression of
androstenedione was significant with both metformin doses" - See Metformin at IAS.
-
Intensive Lifestyle Intervention or Metformin on Inflammation and
Coagulation in Participants With Impaired Glucose Tolerance - Diabetes.
2005 May;54(5):1566-1572 - "In men,
the median changes in CRP from baseline to 1 year were -33% in the lifestyle
group, -7% in the metformin group, and +5% in the placebo group. In women,
the changes in CRP from baseline to follow-up were -29% in the lifestyle
group, -14% in the metformin group, and 0% in the placebo group"
-
Administration of B-group vitamins reduces circulating homocysteine in
polycystic ovarian syndrome patients treated with metformin: a randomized
trial - Hum Reprod. 2005 Mar 24 - "These findings suggest that B-group
vitamins and folic acid administration counteract the Hcy-increasing effect
seen with metformin therapy"
-
Effects of metformin on the body composition in subjects with risk factors for type 2 diabetes - Diabetes Obes Metab. 2005 Mar;7(2):189-92 -
"In the metformin group, there was a decrease in fat weight from 25.9 +/- 9.4 to 20.8 +/- 9.2 kg, p < 0.01, an increase in lean weight from 57.05 +/- 13.6 to 61.9 +/- 16.5 kg, p < 0.01, an increase in basal metabolism from 1735 +/- 413 to 1878 +/- 505
calories/day, p < 0.05 and an increase in body water" - See
metformin at IAS
or OffshoreRX.com
. Note: That's a 19.7% decrease in fat (25.9-20.8)/25.9 = 19.7%, a 8.5% increase in lean
weight (61.9-57.05)/57.05 = 8.5% and a 8.2% increase in basal metabolism (1878-1735)/1735 = 8.2%. - Ben
- Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes -
Diabetologia. 2004 Nov 24 - "These data indicate that metformin or gliclazide, rather than glibenclamide, have a potent anti-atherogenic effect in type 2 diabetes"
- Metformin: drug of choice for the prevention of type 2 diabetes and cardiovascular complications in high-risk subjects - Diabetes Metab. 2003 Sep;29(4):121-2 -
"Metformin is unique in being not only as effective as any other oral antidiabetic therapy in controlling blood glucose, but also having an unparalleled clinical database relating to
improved clinical outcomes in pre-diabetic subjects, and patients with established type 2 diabetes"
- Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes -
Diabetes Metab. 2003 Sep;29(4):53-61 - "metformin has been shown to not only contribute to a better glycaemic control but also to induce some weight loss
(especially in the visceral depot) which may contribute to the improvement of the features of the metabolic syndrome. Thus, metformin treatment may represent a relevant element of an integrated lifestyle modification-pharmacotherapy to prevent not only type 2 diabetes but also cardiovascular disease"
- Do effects on blood pressure contribute to improved clinical outcomes with metformin? - Diabetes Metab. 2003 Sep;29(4):62-70 -
"Metformin improves insulin sensitivity in liver and muscle as its primary antihyperglycaemic mechanism of action, and intensive glycaemic
management with metformin significantly reduced the risk of macrovascular diabetic complications in the UK Prospective Diabetes Study. The clinical outcome benefits in the metformin group included a significant reduction in
the risk of stroke (- 41% vs + 14% with sulphonylurea or insulin treatment, p=0.032) ... metformin
significantly improved endothelial function, a key regulator of vascular tone and blood pressure, in type 2 diabetic patients"
- The potential of metformin for diabetes prevention - Diabetes Metab. 2003 Sep;29(4):104-11 -
"Treatment with metformin
significantly reduced the incidence of diabetes in subjects with IGT and high-normal fasting plasma glucose in the DPP. Moreover, metformin was well tolerated, and health economic analyses
suggest that metformin treatment is cost-effective in the US and Europe ... The results of the DPP identify metformin as an effective option for the prevention of diabetes in subjects with IGT and impaired fasting glucose"
- Beneficial effects of metformin on haemostasis and vascular function in man - Diabetes Metab. 2003 Sep;29(4):44-52 -
"Metformin
is a biguanide compound which is antihyperglycaemic, reduces insulin resistance and has cardioprotective effects on lipids, thrombosis and blood flow. Metformin has a weight neutral/weight lowering effect and reduces hypertriglyceridaemia,
elevated levels of PAI-1, factor VII and C-reactive protein. In addition recent studies indicate that metformin has direct effects on fibrin structure/function and stabilises platelets, two important components of arterial
thrombus. The United Kingdom Prospective Diabetes Study (UKPDS) reported that metformin was associated with a 32% reduction in any diabetes related endpoint (p<0.002), a 39% reduction in myocardial infarction (p<0.01) and a
non-significant 29% fall in microvascular complications. The figures for macrovascular complications compare favourably for those described for other cardioprotective agents such as ACE inhibitors and statins. These
findings confirm metformin as first line therapy in the management of obese insulin resistant type 2 diabetes and in the prevention of the vascular complications of this common condition"
- Effect of metformin on insulin sensitivity and insulin secretion in female obese patients with normal glucose tolerance - Diabetes Metab 2003 Apr;29(2 Pt 1):125
- Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome - Endocrine 2003 Apr;20(3):215-8 -
"CRP level was significantly lower in patients using metformin for blood glucose control compared with those using glibenclamide,
5.56 and 8.3 mg/L, respectively ... The data showed that metformin decreases the level of circulating CRP, a marker of inflammation, more than glibenclamide"
- What to Do About the Metabolic Syndrome? - Archives of Internal Medicine, 2/24/03 -
"Substantial data are accumulating to suggest that
lifestyle modification aimed at producing weight loss is an effective treatment for overweight or obese individuals with the metabolic syndrome ... Some physicians prescribe metformin because it can be associated with weight reduction and seems to counteract insulin resistance. However,
metformin is not approved by the Food and Drug Administration as a weight loss drug ... Some might consider the use of weight loss drugs in patients with metabolic syndrome"
- Metformin-Associated Vitamin B12 Deficiency - Archives of Internal Medicine, 10/28/02
- Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity
- Diabetes Obes Metab. 2002 Jan;4(1):49-55 - "sibutramine, orlistat and metformin are all effective and safe medications that reduce cardiovascular risk and can decrease the risk of type 2 diabetes mellitus in obese females. Overall, treatment with 10mg sibutramine bid is more effective than orlistat or
metformin therapy in terms of weight reduction"
Related Searches:
70220
|